Masimo delivered Q3 results that mostly aligned with guidance, yet it faces challenges in its non-healthcare segment.

Fintel reports that on November 6, 2024, Raymond James upgraded their outlook for Masimo (NasdaqGS:MASI) from Market Perform ...

Shares of Masimo Co. (NASDAQ:MASI – Get Free Report) have received an average rating of “Moderate Buy” from the seven ...

Masimo Corporation MASI is well-poised for growth ... However, concerns regarding overdependence on its Signal Extraction Technology (“SET”) unit and macroeconomic issues persist.

Masimo (NASDAQ:MASI) is set to give its latest quarterly earnings report on Tuesday, 2024-11-05. Here's what investors need to know before the announcement. Analysts estimate that Masimo will ...

Masimo (Nasdaq:MASI) shares ticked up before hours today on third-quarter results that came in ahead of the consensus ...

The lawsuit resulted in five of Masimo’s claims being rejected, and a jury being unable to reach agreement on the rest. That will see a new trial held, at a date yet to be set. Masimo got its ...

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. TipRanks is the most comprehensive data set of sell side ...

Masimo Corp. is a global technology company, which engages in the development, manufacture, and marketing of patient monitoring technologies, and automation and connectivity solutions. Its ...

Masimo MASI2.20%increase; green up pointing triangle said Joe Kiani, who previously informed the board of his decision to resign as chief executive, has been terminated by the company. Kiani’s ...

Apple convinced a federal jury on Friday that health monitoring tech company Masimo’s smartwatches infringe two of its design patents. The jury, in Delaware, agreed with Apple that Masimo ...

The consensus rating for Masimo is Buy, based on 2 analyst ratings. With an average one-year price target of $167.5, there's a potential 16.14% upside.